Lineage Cell Therapeutics
LCTX
LCTX
107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.
Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K
Top Buyers
1 |
1
BlackRock
New York
|
$12.2M |
2 |
2
Vanguard Group
Malvern,
Pennsylvania
|
$9.15M |
3 |
3
State Street
Boston,
Massachusetts
|
$4.59M |
4 |
4
Two Sigma Investments
New York
|
$366K |
5 |
5
Geode Capital Management
Boston,
Massachusetts
|
$2.39M |